Good MorningEquity markets are bracing for what could be a very frosty winter for the stock market. The lingering rise in inflation coupled with the rise of FOMC interest rates has the outlook for S&P 500 earnings in decline and that is the single most important factor to lead the stock market. In this light, the S&P 500 could be expected to fall back to previous lows near 3,500 sometime early in the New Year. The question is when it will be hit and how low the bottom will be when the market gets there. If the outlook for earnings continues to deteriorate the S&P 500 could easily slip below support at the 3,500 level and continue its plunge deeper into correction territory.
The risk for the market this week is almost entirely in the economic data. There are several important reports due out this week including the ADP and NFP reports on employment. The takeaways will be the level of employment and the pace of wage inflation. If either holds true to trends that include steady job gains and mid-single-digit levels of wage inflation the market will not take the news well. Featured: Wall Street Legend: The Top 11 Stocks for 2023 (IPM) 
|
Markets | | |
Due to the continual interest rate hikes by the Federal Reserve over the last twelve months, it has become increasingly likely that the US will head into a recession, likely sometime within the first quarter of next year.
For this reason, investors are rushing toward defensive safe havens to... Read the Full Story |
|
From Our PartnersLouis Navellier's system has identified 18 stocks that rose 10,000% or higher... and more than 675 stocks that went up 100%... not to mention the No. 1 stock in the S&P 500 each and every year, for a decade, from 2012 to 2021. Now he's releasing his list of the Top 11 stocks for 2023. | | | | Click here to download this list for free. |
|
Tech | | | Wall Street capped a quiet day of trading with more losses Friday, as it closed the book on the worst year for the S&P 500 since 2008.
The benchmark index finished with a loss of 19.4% for 2022, or 18.1%, including dividends. It's just its third annual decline since the financial... Read the Full Story |
|
Stocks | | |
In what was a forgettable 2022 for the S&P 500, the information technology sector declined -28%, on par with REITs for the year’s worst economic group.
A surge in interest rates, 40-year high inflation and the Russia-Ukraine conflict, put relentless pressure on technology and other grow... Read the Full Story |
|
From Our PartnersLouis Navellier's system has identified 18 stocks that rose 10,000% or higher... and more than 675 stocks that went up 100%... not to mention the No. 1 stock in the S&P 500 each and every year, for a decade, from 2012 to 2021. Now he's releasing his list of the Top 11 stocks for 2023. | | | | Click here to download this list for free. |
|
Markets | | | Stocks fell in afternoon trading on Wall Street Friday as major indexes close out a dismal year with lingering concerns about stubbornly hot inflation and a potential recession.
The S&P 500 fell 0.8% as of 3:13 p.m. Eastern. The index, which is considered a benchmark for the broad... Read the Full Story |
|
Markets | | |
Enterprise data storage solutions provider Pure Storage Inc. (NYSE: PSTG) stock closed out 2022 with a (-16.5%) loss. Much of the selling in the shares was attributed to the weakening demand for storage chips, as warned by DRAM maker Micron Technology Inc. (NASDAQ: MU).
Micron warned of continued... Read the Full Story |
|
From Our PartnersIf you had bought Netflix after the dot-com crash, you could have turned $1,000 into over half a million dollars in profit. And today – thanks to the tech crash – you have a similar opportunity. Luke Lango just named 5 tech stocks with 10x potential in a new report (one is trading for just $6). | | | | Click here to claim your copy. |
|
Markets | | |
Diversified energy utility Duke Energy Co. (NYSE: DUK) stock has been resilient throughout 2022 as shares closed out the year virtually flat compared to the (-20%) drop in the S&P 500 (NYSEARCA: SPY). The Company operates three divisions comprised of Electric Utilities and Infrastructure, Gas ... Read the Full Story |
|
Markets | | | Democrats in Congress released thousands of pages of former President Donald Trump's tax returns Friday, providing the most detailed picture to date of his finances over a six-year period, including his time in the White House, when he fought to keep the information private in a break with decades o... Read the Full Story |
|
Markets | | | Major Japanese companies have grown more pessimistic about the economy, given higher costs and a weaker yen, according to a survey by Kyodo News.
The survey of 117 companies found just over half, or 56%, expect the economy to grow this year. That was down sharply from 84% a year earl... Read the Full Story |
|
Tech | | | Israel’s military fired missiles toward the international airport of Syria's capital early Monday, putting it out of service and killing two soldiers and wounding two others, the Syrian army said.
The attack, which occurred shortly after midnight Sunday, was the second in seven months... Read the Full Story |
|
Markets | | |
Analysts rated shares of Tyson Foods Inc. (NYSE: TSN) a hold, opting for caution throughout 2022. The MarketBeat analyst consensus rating creeped toward a bullish position. We estimate that the stock offers a potential value opportunity at around $60.
Tyson ranks as the fifth largest f... Read the Full Story |
|
Tuesday's Early Bird Stock Of The Day Prometheus Biosciences, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR300, a G-protein coupled receptor modulator for IBD and potentially other immune-mediated diseases; PRA052, an anti-CD30L mAb for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; and PR2100, an anti-inflammatory cytokine mAb for IBD, and inflammatory and fibrotic diseases. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH for PRA052; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California. As of June 16, 2023, Prometheus Biosciences, Inc. operates as a subsidiary of Merck & Co., Inc. | | View Today's Stock Pick |
|
